A recent study characterized the expression of ADC targets across ovarian cancer histotypes. Findings suggest ...

An expert discusses how real-world evidence and patient-reported outcomes support luspatercept’s clinical benefits, while ...

An expert discusses how optimal sequencing of therapies remains unclear in lower-risk MDS, with emerging combination ...

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

Zydus Lifesciences gains FDA tentative approval for generic ibrutinib, enhancing access to vital cancer treatment for ...

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for ...

A multicenter study evaluating lurbinectedin in patients with extensive-stage small cell lung cancer who received second-line ...

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination ...